title: Hidradenitis suppurativa treated with combination of infliximab and dapsone.
abstract: Hidradenitis suppurativa (HS) is chronic inflammatory disease characterized by recurrent painful nodules, which leads to forming an abscess and sinus tracts, together with pustulation and hypertrophic scarring in the areas of apocrine sweat glands. Systemic and local antibiotic therapy, together with corticoid therapy, sulphonates, retinoids and surgical treatment with incisions and drainage belongs to actual treatment possibilities. Biological therapy represents the absolute peak in the treatment last years, mostly TNFα-inhibitors. Even though their very good short term effect is described, long term keeping up the good long effect of the treatment is not achieved with satisfaction. This is the reason to reach for traditional therapeutic possibilities combined with biological treatment in cases of torpid and resistive disease. In the following article a case report of a patient with hidradenitis suppurativa treated subsequently with combination of TNFα-inhibitors and dapson (Fig. 6, Ref. 19).
authors.affiliation: Department of Dermatovenerology, University Hospital, Bratislava, Slovakia. peter.kozub@laposte.net
authors.forename: P
authors.initials: P
authors.lastname: Kozub
authors.forename: M
authors.initials: M
authors.lastname: Simaljakova
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003622:Dapsone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D003622:Dapsone; D000069285:Infliximab